BIOINFORMATICS/INSILICO R&D

 

 

Here we will be revealing how functional genomics connected with EHR and a host of other metadata are being used to drive forward an end-to-end target discovery process. This along with new toolkits provided to us through the likes of CRISPR allow us to produce truly personalised medicines, reducing costs and getting therapy to patients at new breakneck speeds. We will be dipping into the new structures at various world leading pharma companies to see how the drug and target discovery process is changing and what the next steps are for the industry.
 

THIS YEAR’S WORLD LEADING BIOINFORMATICS/INSILICO R&D SPEAKERS

 

 

 

Bioinformatics & Insilico R&D, Tuesday 2 November 2021

10:40

Networking Break

Iris Grossman
Bioinformatics & Insilico R&D
11:40

Combining massively parallel assays, synthetic biology and statistical learning to generate hyper-potent RNAi therapeutics

Sandro Morganella
Bioinformatics & Insilico R&D
12:00

Supporting precision medicine via AI-powered variants landscape

Dirk Van Hyfte
Bioinformatics & Insilico R&D
12:40

HYFT, A new approach to completely integrate and structure large scale multi-omic data.

13:20

Networking Lunch Break

Peter Grandsard
Bioinformatics & Insilico R&D
14:20

Insilco design of therapeutics for well characterised diseases

Jonathan Woodsmith
Bioinformatics & Insilico R&D
15:00

Clinically relevant oncology discoveries using multi-omic analyses

Comprehensive high quality multi-omics and clinical data combined with AI-integrated advanced analytics can drive discoveries within precision oncology approaches.Here we present this discovery power and highlight how we can define novel sub-types of non-small cell lung cancer through integration of molecular and clinical datasets. Our unique, high quality proteomic and phospho-proteomic dataset produced by Biognosys act as a basis for further characterization of these sub-types and can drive clinically relevant oncology discoveries that can inform precision medicine approaches.Driven by our mission to unveil the complex mechanisms of cancer and to advance precision oncology, Indivumed combines the world’s most comprehensive multi-omics database IndivuType with extensive clinical experience and the AI-integrated advanced analytics platform nRavel®.
Bioinformatics & Insilico R&D
15:40

BIOGNOSYS

16:20

Networking Break

Bioinformatics & Insilico R&D
16:55

Chair Remarks

Valdemar Stentoft-Hansen
Bioinformatics & Insilico R&D
17:00

Accelerating scientific discoveries with explainable AI: A breast cancer example

Data has the potential to lead to knowledge. But how do we best extract knowledge from data? Explainable AI holds the promise of delivering predictions that are understandable to a human mind. In this talk we present a story around predicting breast cancer outcome based on a set of different genomics data types. We show what it means to cut through the noise and reveal the signal: in this case we're talking about the biological molecules that interact in non-trivial ways to reveal what's important in breast cancer survival. Tune in to see how Abzu is pushing the boundaries of its unique technology to bring us closer to the promise of precision medicine.
Bioinformatics & Insilico R&D
17:20

Reserved_Regulatory Transformation through Big Data

18:00

Neri & Sons Band & Networking Drinks Reception

last published: 19/Oct/21 21:45

Bioinformatics & Insilico R&D, Wednesday 3 November 2021

10:20

Networking Break + Speed Networking

Steve Rees
Bioinformatics & Insilico R&D
11:20

Target Identification through Functional Genomics

  • The discovery of novel drug targets is the critical first step in the creation of medicines to treat disease
  • Functional Genomics describes the screening of genome-wide CRISPR libraries in cellular disease models to examine the effect on biology of the deletion or up-regulation of every gene
  • Functional Genomics is being used to identify genes involved in many disease processes
  • Functional Genomics is being used to identify genes that sensitise cells or drive resistance to cancer medicines
Bioinformatics & Insilico R&D
11:40

Reserved - Millipore Sigma

Guillermo del Angel
Bioinformatics & Insilico R&D
11:50

Integrating diverse data sets for rare diseases

  • Functional genomics signatures
  • Deep characterisation of mutations
  • Longitudinal EMR’s
  • Deep population genomics
Fernando Ulloa Montoya
Bioinformatics & Insilico R&D
12:20

Translational genomics for vaccines: Characterizing individual vaccine response and disease heterogeneity

  • Genomics applications in prophylactic and therapeutic vaccines
  • Biomarkers for vaccine protection and patient stratification
Joanna Betts
Bioinformatics & Insilico R&D
12:40

Integration of genetics and genomics for target identification and clinical translation

13:00

Networking Lunch Break

Morten Sogaard
Bioinformatics & Insilico R&D
14:00

Considerations for target discovery and validation integrating genetics and bioinformatics

16:00

Networking Break

Panel discussion
Bioinformatics & Insilico R&D
17:00

Start Up Pitches

18:00

Drinks Reception

last published: 19/Oct/21 21:45

Bioinformatics & Insilico R&D, Thursday 4 November 2021

last published: 19/Oct/21 21:45

GET INVOLVED AT BIODATA WORLD CONGRESS

 

 

TO SPONSOR


Alistair Wilmot
alistair.wilmot@terrapinn.com
0207 092 1174

 

 

TO SPEAK


Edward Glanville

edward.glanville@terrapinn.com
0207 092 1042

 

 

MARKETING OPPORTUNITIES


Onika Akhtar
onika.akhtar@terrapinn.com
0207 092 1034